share_log

EF Hutton Reiterates Buy on Adaptimmune Therapeutics, Maintains $10 Price Target

Benzinga ·  Aug 10, 2023 04:47

EF Hutton analyst Tony Butler reiterates Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment